Back

Impact of hyperaldosteronism in adults with hypertension: effects on long term risk of cardiovascular disease and all cause death

28 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Aldosterone and hypertension Renin-Angiotensin System ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Antonio Angelico-Goncalves

Unidade local de Saude Gaia/Espinho EPE, Vila Nova de Gaia (Portugal)

5 More presentations in this session

Presentation thumbnail
Opportunistic aldosterone testing during hypokalemia as an alternative confirmatory test for primary aldosteronism
Miss K. L (Singapore, SG)
Abstract Slides
Presentation thumbnail
Metabolic and inflammatory phenotypic divergence between primary aldosteronism and essential hypertension: a propensity score-matched cohort study
Professor T. Liu (Tianjin, CN)
Abstract Slides
Presentation thumbnail
Efficacy and safety of baxdrostat in resistant and uncontrolled hypertension: a systematic review and meta-analysis of randomised controlled trials
Ms J. Ferraz De Sousa (BR)
Presentation thumbnail
Eplerenone vs irbesartan as first line therapy in obese hypertensive patients: results of the HEBRO randomized controlled trial
Doctor P. Iliakis (Athens, GR)
Abstract Slides
Presentation thumbnail
Baxdrostat for treatment of uncontrolled and resistant hypertension: a meta-analysis and systematic review
Doctor A. Bortolotto (Sao Paulo, BR)
Abstract Slides

Access the full session

Session thumbnail
Aldosterone and hypertension

The Event

Event poster

ESC Congress 2026

28 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Role of subclinical primary aldosteronism in valvular and vascular calcification: a population-based cohort study
1 September 2025
thumbnail
Congress Presentation
The impact of resting heart rate measured on cardiovascular events in subject with hypertension.
31 August 2020
thumbnail
Congress Presentation
Long-term outcomes in heart failure with preserved ejection fraction: predictors of cardiovascular and non-cardiovascular mortality
30 June 2021
thumbnail
ESC Journals
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial
29 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources